NEW YORK, June 22 (GenomeWeb News) - Immusol and Affymetrix have signed onto a scientific collaboration in which Immusol will use Affymetrix's gene chips in cancer drug discovery, the companies said today.
Under the collaboration, Immusol, of San Diego, will use Affymetrix's microarrays to conduct gene expression profiling on its engineered tumor cells, and identify pathways related to cancer. The program also aims to "acquire and validate additional therapeutic target candidates," the parties said. The scientists plan to obtain information about the molecular mechanism of actions of drugs or drug targets through perturbing the system and observing the results.
The parties did not disclose the financial terms of the agreement.